Abstract 1299P
Background
The purpose of this study was to evaluate the safety and efficacy of subsequent radiotherapy after first-line durvalumab plus chemotherapy in extensive-stage small cell lung cancer (ES-SCLC).
Methods
A total of 122 patients with ES-SCLC from three hospitals during July 2019 to December 2021 were retrospectively analyzed. Inverse probability of treatment weighting (IPTW) analysis was performed to address potential confounding factors. We primarily evaluated the progression-free survival (PFS) and overall survival (OS) in association with radiotherapy.
Results
After IPTW analysis, 49 patients received durvalumab plus chemotherapy with subsequent radiotherapy (Durva+EP+RT) and 72 patients received immunochemotherapy (Durva+EP). The median OS was 17.2 vs 12.3 months (hazard ratio (HR): 0.38; P=0.020), respectively, and the median PFS was 8.9 vs 5.9 months (HR: 0.56; P=0.030), respectively. Thoracic radiation therapy (TRT) resulted in longer OS (17.2 vs 14.7 months) and PFS (9.1 vs 7.2 months) compared to radiotherapy directed to other metastatic sites. Among patients with oligo-metastasis, radiotherapy also showed significant benefits, with a median OS of 17.4 vs 13.7 months and median PFS of 9.8 vs 5.9 months compared to no radiotherapy. Continuous durvalumab treatment beyond progression (TBP) prolonged OS compared to patients without TBP, in both the Durva+EP+RT (NA vs 15.8 months, HR: 0.48) and Durva+EP groups (12.3 vs 4.3 months, HR: 0.29). Grade 3 or 4 adverse events occurred in 13 (26.5%) and 13 (18.1%) patients, respectively, in the two groups; pneumonitis was mostly low-grade.
Conclusions
Addition of radiotherapy after first-line immunochemotherapy significantly improved survival outcomes with manageable toxicity in ES-SCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Bethune-Cancer Radiotherapy Translational Medicine Research Fund of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1287P - Comparing the cost-effectiveness of perioperative immunotherapy strategies in non-small cell lung cancer
Presenter: Bharathi Muthusamy
Session: Poster session 04
1288P - Neoadjuvant therapy with anti-PD-1/PD-L1 plus platinum-base chemotherapy for resectable stage II-III non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials
Presenter: Maria Dacoregio
Session: Poster session 04
1289TiP - LANTERN study: A multi-omics digital human avatar for integrating precision medicine into clinical practice for lung cancer patients
Presenter: Emilio Bria
Session: Poster session 04
1294P - A final analysis of a phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non–small-cell lung cancer: TORG1937 (DATE study)
Presenter: Tetsuro Kondo
Session: Poster session 04
1296P - Neoadjuvant camrelizumab and apatinib in patients with resectable non-small-cell lung cancer: One-year update from a phase II trial
Presenter: Wei Guo
Session: Poster session 04
1297P - An open-label, prospective phase II study of tislelizumab in combination with chidamide as consolidation therapy in locally advanced, unresectable, stage III NSCLC
Presenter: Yi Hu
Session: Poster session 04
1298P - Chemotherapy with concurrent proton vs. photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and immune therapy
Presenter: Francesco Cortiula
Session: Poster session 04
1300P - Treatment and clinical outcome in recurrent/refractory locally advanced NSCLC following chemoradiotherapy and consolidative durvalumab
Presenter: Georg Evers
Session: Poster session 04